Collagen, Type I (COL1) Antikörper

Antigen: Collagen, Type I (COL1)

Klonalität: Polyklonal

Wirt: Ziege

Reaktivität: Human

Applikation: Immunhistochemie (IHC), Immunpräzipitation (IP)

Produktnummer: ABIN135046

Produktbeschreibung

Weitere Bezeichnung: Type I Collagen

Format: Purified

Beschreibung: Reacts with conformational determinants on human type I collagen as demonstrated by ELISA. May react with type I collagen from other species. Exhibits <10% cross reactivity with collagen type II, III, IV, V and VI. The antibody has not been tested for reactivity with other ECM proteins (e.g., laminin, fibronectin).

Anwendungen

Applikationshinweise: WORKING DILUTIONS Immunocytochemistry/ Immunohistochemistry: Purified (1:10-1:20), Biotin (1:20-1:40). ELISA: Biotin (1:1000-1:4000). Since applications vary, you should determine the optimum working dilution of the product that is appropriate for your specific need. *Please note that harsh chemicals or procedures involving heat may denature collagen epitopes needed for proper binding. We recommend avoiding such applications when using this antibody.

Lagerung: The purified (UNLB) antibody is supplied as 0.2 mg of purified immunoglobulin in 0.5 mL (C = 0.4 mug/mL) of 100 mM borate buffered saline, pH 8.0. No preservatives or amine-containing buffer salts added. Store at 2-8C. The biotin (BIOT) conjugate is supplied as 0.2 mg in 0.5 mL (C = 0.4 mug/mL) of PBS/NaN3. Store at 2-8C. Reagents are stable for the period shown on the label if stored as directed. WARNING Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Publikationen

Publikationen: Kompa, Wang, Phrommintikul et al.: "Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy." in: Peptides, 2010 (PubMed).

Herman-Edelstein, Thomas, Thallas-Bonke et al.: "Dedifferentiation of immortalized human podocytes in response to transforming growth factor-β: a model for diabetic podocytopathy." in: Diabetes, Vol. 60, Issue 6, pp. 1779-88, 2011 (PubMed).

Liu, Chen, Huang et al.: "C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes." in: Diabetologia, Vol. 54, Issue 10, pp. 2713-23, 2011 (PubMed).

Haines, Hant, Lafyatis et al.: "Elevated expression of cav-1 in a subset of SSc fibroblasts contributes to constitutive Alk1/Smad1 activation." in: Journal of cellular and molecular medicine, 2012 (PubMed).

Kanzaki, Yamato, Takagi et al.: "Controlled collagen crosslinking process in tissue-engineered fibroblast sheets for preventing scar contracture on the surface of lungs." in: Journal of tissue engineering and regenerative medicine, 2012 (PubMed). Von den Autoren verwendete Methode: Immunohistochemistry (IHC) (1:50).

Haller, Kennedy, Shidyak et al.: "Monoclonal Antibody Against Marinobufagenin Reverses Cardiac Fibrosis in Rats With Chronic Renal Failure." in: American journal of hypertension, 2012 (PubMed).

Liu, Zhang, Mao et al.: "A Crosstalk between the Smad and JNK Signaling in the TGF-β-Induced Epithelial-Mesenchymal Transition in Rat Peritoneal Mesothelial Cells." in: PLoS ONE, Vol. 7, Issue 2, pp. e32009, 2012 (PubMed).